Novel Medications for Opiate Detoxification - 4 | NCT00000279

Studies
Novel Medications for Opiate Detoxification - 4

NCT00000279

Sponsor

Yale University

Status

Completed

Last Update Posted

Jun 18, 2020Actual

Enrollment

Phase

Phase 2

Conditions

Opioid-Related Disorders
Substance-Related Disorders

Interventions

Clonidine

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
P50DA009250	U.S. NIH Grant/Contract		View source
P50-09250-4

Status Module

Record Verification Date

Jun 2020

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Sep 1994

Primary Completion Date

Aug 1999Actual

Completion Date

Aug 1999Actual

First Submitted Date

Sep 20, 1999

First Submission Date that Met QC Criteria

Sep 20, 1999

First Posted Date

Sep 21, 1999Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 17, 2020

Last Update Posted Date

Jun 18, 2020Actual

Name	Class
National Institute on Drug Abuse (NIDA)	NIH
VA Connecticut Healthcare System	FED

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 2

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

Name	Type	Description	Arm Group Labels	Other Names
Clonidine	Drug

Measure	Description	Time Frame
Withdrawal severity

Eligibility Module

Eligibility Criteria

Please contact site for information.

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Thomas R Kosten, M.D.	VA Connecticut Healthcare System	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
VA Connecticut Healthcare System		New Haven	Connecticut	06519	United States

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
	Background	AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.

ID	Term
D000079524	Narcotic-Related Disorders
D064419	Chemically-Induced Disorders
D001523	Mental Disorders

ID	Term
D048288	Imidazolines
D007093	Imidazoles
D001393	Azoles
D006573	Heterocyclic Compounds, 1-Ring

ID	Term
D009293	Opioid-Related Disorders
D019966	Substance-Related Disorders